Phenytoin

證據等級: L5

預測適應症: 10 個

Phenytoin: From Epilepsy to Trigeminal Neuralgia

One-Sentence Summary

Phenytoin is a classic hydantoin-class anticonvulsant, long used for seizure control. The TxGNN model’s highest-scoring prediction (“trigeminal nerve neoplasm”) was flagged by the underlying evidence review as a likely false positive with no plausible antineoplastic mechanism, so this report instead focuses on the model’s next-best, evidence-supported candidate: Trigeminal Neuralgia, which is backed by 1 completed clinical trial and 19 supporting publications, including a European Academy of Neurology guideline.

Note on candidate selection: TxGNN’s #1-ranked prediction (trigeminal nerve neoplasm, score 99.99%) was reviewed and judged a pseudo-positive pairing — the retrieved literature actually concerns trigeminal neuralgia and Sturge-Weber syndrome, not tumour biology, and phenytoin has no known antineoplastic mechanism. Ranks #2–#8 (audiogenic seizures, startle epilepsy, micturition/eating/orgasm/thinking/reading-induced seizures) are all rare reflex-epilepsy subtypes with only preclinical animal-model or case-report support (L4–L5, Hold/Research Question). Rank #9, trigeminal neuralgia, is the only candidate with a completed prospective clinical trial and guideline-level literature, and is therefore the focus of this evaluation.

Quick Overview

Item	Content
Original Indication	Not formally documented in this evidence pack (drug is unmarketed locally); established clinical use is seizure/epilepsy control
Predicted New Indication	Trigeminal Neuralgia
TxGNN Prediction Score	99.97% (rank 1399)
Evidence Level	L2
Market Status	✗ Not Marketed (0 active licenses)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed formal mechanism-of-action documentation was not available in this evidence pack (marked as a data gap). Based on well-established pharmacology, phenytoin is a voltage-gated sodium channel blocker that stabilizes hyperexcitable neuronal membranes and suppresses high-frequency repetitive firing — the same mechanism underlying its efficacy in epilepsy.

Trigeminal neuralgia is characterized by paroxysmal, high-frequency ectopic discharges in the trigeminal ganglion/root entry zone, a pathophysiology mechanistically analogous to epileptic hyperexcitability. This is why carbamazepine and oxcarbazepine — sodium channel blockers structurally related to phenytoin — are first-line therapies for trigeminal neuralgia. Phenytoin’s same channel-blocking action provides a strong mechanistic rationale for its use, and it is already established in neurology practice as an intravenous rescue treatment for acute trigeminal neuralgia exacerbations when oral first-line agents are impractical (e.g., during dehydration or inability to swallow).

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03712254	N/A	Completed	15	Prospective systematic study of IV phenytoin as acute rescue treatment for exacerbations of trigeminal neuralgia, addressing the clinical gap when oral first-line agents (carbamazepine/oxcarbazepine) cannot be used during severe flares.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30860637	2019	Guideline	European Journal of Neurology	EAN clinical practice guideline on trigeminal neuralgia diagnosis and management
31908187	2020	Review	Molecular Pain	Overview of TN pathophysiology and pharmacological treatment mechanisms
28761370	2017	Review	Journal of Pain Research	Comparative review of phenytoin vs. carbamazepine evidence base in TN
35469475	2022	Cohort	Cephalalgia	Retrospective analysis of 144 cases: IV lacosamide and phenytoin for acute TN exacerbations
32981076	2020	Case series	Headache	Retrospective cohort on IV phenytoin as acute rescue treatment for TN crisis
29114270	2017	Review	Asian Journal of Neurosurgery	Clinical overview of TN diagnosis, mechanism, and anticonvulsant-based treatment
19445753	2009	Review	BMJ Clinical Evidence	Summary of TN clinical presentation and evidence-based treatment options

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: One completed prospective clinical trial plus a retrospective cohort of 144 cases and guideline-level literature support intravenous phenytoin as an established off-label rescue therapy for acute trigeminal neuralgia exacerbations, consistent with its sodium-channel-blocking mechanism shared with first-line agents (carbamazepine/oxcarbazepine). Evidence level is L2 — sufficient to proceed cautiously, but not yet supported by a dedicated randomized controlled trial.

To proceed, the following is needed:

TFDA-approved package insert (warnings, contraindications) — currently a Blocking data gap preventing formal safety (S1) evaluation
Confirmed DrugBank/formal MOA documentation
Local market access assessment, since the drug currently holds 0 active licenses (未上市/Not Marketed) in this jurisdiction
Cardiac/hemodynamic monitoring protocol for IV administration, given phenytoin’s narrow therapeutic index and known infusion-related risks (arrhythmia, hypotension)
A prospective RCT comparing IV phenytoin to standard-of-care rescue options to upgrade evidence level beyond L2
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.